The glucagon‐like peptide‐1 receptor agonist semaglutide in diabetic kidney disease: A new kid on the block to afford maximal kidney protection

Documenti analoghi

• Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
  di: Mehmet Kanbay, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
  di: Andrea Saglietto, et al.
  Pubblicazione: (2024)
• Effects of glucagon‐like PEPTIDE‐1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META‐analysis
  di: Andrea Pasta, et al.
  Pubblicazione: (2025)
• Mineralocorticoid receptor antagonists in kidney transplantation
  di: Mehmet Kanbay, et al.
  Pubblicazione: (2024)
• Type 2 diabetes and chronic kidney disease as long‐term predictors of cardiovascular events in patients with coronary artery disease
  di: Laura Schnetzer, et al.
  Pubblicazione: (2024)